Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

This study has been completed.
Sponsor:
Collaborator:
The Medicines Company
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00952081
First received: July 29, 2009
Last updated: November 18, 2013
Last verified: November 2013
Results First Received: June 22, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Hypertension
Brain Tumor
Epilepsy
Intervention: Drug: Clevidipine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients scheduled for intracranial surgery were prospectively enrolled after giving consent. Clevidipine (0.5 mg/mL in 20% lipid solution, which was to be initiated at 10 mg/h and titrated to effect) was administered as the primary antihypertensive agent for perioperative hypertension, with target BPs of less than 130mm Hg.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Clevidipine,Brain Tumor,Hypertension Clevidipine(0.5 mg/mL in 20% lipid solution), initiated at 10 mg/h and titrated to effect, was administered as the primary antihypertensive agent for perioperative hypertension, with target BPs of less than 130mm Hg.

Participant Flow:   Overall Study
    Clevidipine,Brain Tumor,Hypertension  
STARTED     22  
COMPLETED     22  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Clevidipine,Brain Tumor,Hypertension 21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia

Baseline Measures
    Clevidipine,Brain Tumor,Hypertension  
Number of Participants  
[units: participants]
  22  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     21  
>=65 years     1  
Age  
[units: years]
Mean ± Standard Deviation
  54  ± 14.25  
Gender  
[units: participants]
 
Female     12  
Male     10  
Region of Enrollment  
[units: participants]
 
United States     22  



  Outcome Measures

1.  Primary:   The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine is a Sole Antihypertensive Agent Used for Blood Pressure Control)   [ Time Frame: intraoperatively and 90 min after surgery ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Alex Bekker, MD, PhD
Organization: UMDNJ
phone: 973-972-5007
e-mail: bekkeray@umdnj.edu


No publications provided


Responsible Party: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00952081     History of Changes
Other Study ID Numbers: 08-745
Study First Received: July 29, 2009
Results First Received: June 22, 2012
Last Updated: November 18, 2013
Health Authority: United States: Institutional Review Board